Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Chengdu Suncadia Medicine obtained marketing approval for its Licancopan Fumarate Capsules from China's National Medical Products Administration.
The approved indication is for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy, according to a Thursday bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.